Search company, investor...

InterMune

intermune.com

Founded Year

1998

Stage

Acq - P2P | Acquired

Total Raised

$46.13M

Valuation

$0000 

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and orphan fibrotic diseases. In pulmonology, the company is focused on therapies for the treatment of idiopathic pulmonary fibrosis (IPF), a progressive, irreversible, unpredictable and ultimately fatal lung disease. InterMune's research programs are focused on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases.

Headquarters Location

3280 Bayshore Boulevard

Brisbane, California, 94005,

United States

415-466-2200

Missing: InterMune's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: InterMune's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

InterMune Patents

InterMune has filed 85 patents.

The 3 most popular patent topics include:

  • Carboxylic acids
  • Autoimmune diseases
  • Inflammations
patents chart

Application Date

Grant Date

Title

Related Topics

Status

6/27/2019

1/26/2021

Lung disorders, Pneumonia, Autoimmune diseases, Inflammations, Rare diseases

Grant

Application Date

6/27/2019

Grant Date

1/26/2021

Title

Related Topics

Lung disorders, Pneumonia, Autoimmune diseases, Inflammations, Rare diseases

Status

Grant

Latest InterMune News

Melinta Therapeutics nabs FDA nod for more convenient rework of antibiotic Orbactiv, a former Eli Lilly candidate

Mar 15, 2021

Nicole DeFeudis Associate Editor As pres­sure ris­es to ad­dress the su­per­bug cri­sis, Melin­ta Ther­a­peu­tics says it now has a more con­ve­nient op­tion to treat those with an­tibi­ot­ic-re­sis­tant skin in­fec­tions. Chris­tine Ann Miller Melin­ta got the OK for a new-and-im­proved for­mu­la­tion of its an­tibi­ot­ic ori­ta­vancin in acute bac­te­r­i­al skin and skin struc­ture in­fec­tions (AB­SS­SI) caused by sus­cep­ti­ble iso­lates of Gram-pos­i­tive mi­croor­gan­isms, in­clud­ing MR­SA, the com­pa­ny an­nounced on Mon­day. The drug, mar­ket­ed as Kimyr­sa, can be ad­min­is­tered over one hour as op­posed to Melin­ta’s ear­li­er Or­bac­tiv, which takes three. “We have re­spond­ed to the re­quests of the med­ical com­mu­ni­ty to pro­vide an ori­ta­vancin prod­uct with a short­er in­fu­sion time,” CEO Chris­tine Ann Miller said in a state­ment. “We be­lieve that with the ap­proval of KIMYR­SA and prod­uct avail­abil­i­ty this sum­mer, physi­cians and pa­tients will now have a com­pelling new one-dose al­ter­na­tive to the cur­rent stan­dard of mul­ti-dose reg­i­mens for AB­SS­SI.” Ori­ta­vancin’s long jour­ney to ap­proval, be­gin­ning in Eli Lil­ly’s pipeline, is rep­re­sen­ta­tive of the state of af­fairs in an­tibi­otics, a high-risk field from which Big Phar­ma re­treat­ed years ago. Many an­tibi­otics fail in de­vel­op­ment, while oth­ers with­er on the vine due to a lack of avail­able fund­ing. And for the ones that do make it to mar­ket, it’s an up­hill bat­tle against cur­rent­ly ex­ist­ing op­tions and cheap gener­ics. Lil­ly sold the world­wide rights to ori­ta­vancin to In­ter­Mune in 2001. Four years lat­er, In­ter­Mune sold the drug to Tar­gan­ta Ther­a­peu­tics, which was on the hunt for “crit­i­cal­ly need­ed” an­tibi­otics to treat an­tibi­ot­ic-re­sis­tant in­fec­tions. In 2008, though, the FDA sent Tar­gan­ta back to the clin­ic, is­su­ing it a CRL for ori­ta­vancin in com­pli­cat­ed skin and skin struc­ture in­fec­tions. The fol­low­ing year, The Med­i­cines Com­pa­ny lined up a $42 mil­lion deal to buy out Tar­gan­ta and the Phase III drug. “We be­lieve that ori­ta­vancin can be­come an im­por­tant an­ti-in­fec­tive for se­ri­ous in­fec­tions in­volv­ing dif­fi­cult-to-treat bac­te­ria in dif­fi­cult-to-treat hos­pi­tal­ized pa­tients,” the com­pa­ny an­nounced. “Many of those crit­i­cal­ly ill pa­tients are the same pa­tients treat­ed with our ex­ist­ing prod­ucts.” The FDA ap­proved ori­ta­vancin in 2014 for AB­SS­SIs caused by sus­cep­ti­ble Gram-pos­i­tive bac­te­ria, based on two tri­als dubbed SO­LO I and SO­LO II. The SO­LO tri­als com­pared ori­ta­vancin to van­comycin, an­oth­er Lil­ly orig­i­nal that’s now in the hands of ANI Phar­ma­ceu­ti­cals. The stud­ies showed that one 1,200 mg dose of ori­ta­vancin worked just as well as sev­en to 10 days of twice-dai­ly van­comycin treat­ments, ac­cord­ing to Melin­ta. In 2017, Melin­ta ex­e­cut­ed a $270 mil­lion deal to buy out The Med­i­cines Com­pa­ny’s in­fec­tious dis­ease unit — in­clud­ing ori­ta­vancin. In ad­di­tion to the SO­LO tri­als, the FDA based its lat­est ap­proval for ori­ta­vancin on an open-la­bel phar­ma­co­ki­net­ics study, which com­pared a one-hour Kimyr­sa treat­ment to a three-hour Or­bac­tiv treat­ment. “Sin­gle-dose, long-act­ing an­tibi­otics, such as KIMYR­SA, may be es­pe­cial­ly ben­e­fi­cial for pa­tients who lack the sup­port or re­sources to ad­here to mul­ti­ple in­tra­venous ad­min­is­tra­tions,” An­drew Dold, an in­fec­tious dis­ease doc­tor in the Greater At­lanta re­gion, said in a state­ment. AUTHOR Jason Mast Editor Joan Butterton was sitting 30,000 feet above the Atlantic, flying to a conference in Europe, when the Merck scientist seated next to her started gushing about the HIV molecule the big pharma had just licensed from a small Japanese company. It was so potent in monkeys, the scientist said, that they couldn’t figure out what the lowest effective dose was and it stayed in the animals for an incredibly long time, far longer than the approved drugs HIV patients took daily. Keep reading Endpoints with a free subscription Unlock this story instantly and join 103,700+ biopharma pros reading Endpoints daily — and it's free. SIGN UP John Carroll Editor & Founder Back in the spring of 2014, Versant put together a tidy $25 million launch round for a small upstart with big dreams called CRISPR Therapeutics. They had an impressive brain trust, headed by CRISPR/Cas9 innovator — and now Nobel winner — Emmanuelle Charpentier. And that exclusive band of gene editing pioneers included Matt Porteus out of Stanford. CRISPR Therapeutics, of course, went on to become a leader in the gene editing field, now partnered with Vertex on a cutting-edge program for sickle cell disease. The biotech has a market cap brushing up against $10 billion — serious money in an era that’s turned its attention to biotech and the future of medicine. Premium subscription required Kyle Blankenship Managing Editor Despite immense clinical promise, small cell and gene therapy players have faced a chronic manufacturing bottleneck tied to limited cash and specialized expertise. Born from the idea of disrupting the manufacturing business model in that space, ElevateBio has scored its biggest fundraising round yet to clear the logjam. ElevateBio closed a massive $525 million Series C it will use to keep building its next-gen startup engine and one-stop-shop cell and gene therapy manufacturing “ecosystem,” the biotech said Monday. Keep reading Endpoints with a free subscription Unlock this story instantly and join 103,700+ biopharma pros reading Endpoints daily — and it's free. SIGN UP Associate Editor Galecto $GLTO is yanking the top dose of its IPF drug GB0139 in a clinical study after the safety monitoring board flagged an imbalance of adverse events in the study pointing to the therapy. Galecto expects to continue recruiting patients who are not taking nintedanib or pirfenidone at screening and who would be randomized to receive GB0139 3 mg or placebo. The DSMB recommended the patients randomized to the 10mg group and all those taking nintedanib or pirfenidone should be discontinued from the study. Based on these recommendations, the Company plans to work with both the study investigators and the appropriate regulatory authorities to implement these changes promptly. Read More

InterMune Frequently Asked Questions (FAQ)

  • When was InterMune founded?

    InterMune was founded in 1998.

  • Where is InterMune's headquarters?

    InterMune's headquarters is located at 3280 Bayshore Boulevard, Brisbane.

  • What is InterMune's latest funding round?

    InterMune's latest funding round is Acq - P2P.

  • How much did InterMune raise?

    InterMune raised a total of $46.13M.

  • Who are the investors of InterMune?

    Investors of InterMune include Roche Holding, BlackRock, Vector Fund Management, Bain Capital Public Equity, Moore Capital Management and 18 more.

  • Who are InterMune's competitors?

    Competitors of InterMune include Inhibikase Therapeutics, Aquinox Pharmaceuticals, Actinobac Biomed, PrevaCept Infection Control, Trius Therapeutics and 9 more.

Compare InterMune to Competitors

M
MIGENIX

MIGENIX is committed to advancing therapy, improving health, and enriching life by developing and commercializing drugs for the treatment of infectious diseases. The Company's programs include drug candidates for: the prevention of catheter-related infections (Phase III), the treatment of dermatological diseases (end of Phase II), the treatment of chronic hepatitis C infections (Phase II and preclinical), the treatment of serious gram positive bacterial infections (preclinical) and the treatment of hepatitis B infections (preclinical). MIGENIX is headquartered in Vancouver, British Columbia, Canada.

A
Actinobac Biomed

Actinobac Biomed is a biopharmaceutical company developing therapeutics for multiple indications, including blood cancers, autoimmune/inflammatory diseases, and HIV. Its drug candidates are based upon Leukothera (LtxA), a natural protein that targets and eliminates white blood cells (WBCs) involved in the mechanism of many diseases. Products based upon Leukothera are being developed by Actinobac for the treatment of leukemia/lymphoma, dry eye, and psoriasis.

M
MucoVax

MucoVax is specialised in the development and production of milk based antibody therapies for the prevention and dietary management of gastro-intestinal infections in humans as well as in animals.

M
Midway Biome

Midway Biome is a privately-held specialty company located in Philadelphia. Midway was founded by gastrointestinal scientists at the University of Chicago in the Departments of Surgery, Digestive Diseases, Infectious Disease, and an experienced gastroenterologist and biotech entrepreneur. The initial observations leading to products to maintaining health through gut integrity was extended by a scientist in bone physiology at Michigan State University in collaboration with Midway.

L
Lytix Biopharma

Pre clinical developer of lytic peptide drugs for the treatment of resistant bacterial, fungal infections and tumor progression, closed a $10.4M Series D financing. oncology

I
Inimex Pharmaceuticals

Inimex Pharmaceuticals, Inc. is focused on the development and commercialization of Innate Defense Regulators (IDRs), first in class drugs that selectively trigger the body's innate defenses without causing inflammation. IDR products have major market potential for infectious disease, cancer, and inflammatory disease. These products will reduce morbidity and mortality in the rapidly growing population of immune suppressed and elderly patients who are "at-risk" for these disorders. IDR products will also benefit healthcare payors by reducing costs associated with hospitalization. Inimex' lead IDR product IMX942 targets a broad spectrum of life-threatening hospital infections, many of which are caused by antibiotic-resistant bacteria such as methicillin-resistant Staphylococcus aureus (MRSA) or vancomycin-resistant Enterococcus (VRE). IMX942 is active against both normal and drug-resistant bacteria and its ability to stimulate host innate immune defenses is not susceptible to bacterial antibiotic resistance mechanisms. The first clinical indication for IMX942 will be the prevention of infections associated with cancer chemotherapy-induced immune suppression. nnAdditional IDR product candidates will be developed for distinct disease areas, with an emphasis on inflammatory disease and demonstration of the potential for orally available IDR dosage forms.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.